CN Patent

CN107921072A — 微生物群恢复治疗（mrt）组合物和制造方法

Assigned to Rebiotix Inc · Expires 2018-04-17 · 8y expired

What this patent protects

公开了微生物群恢复治疗(MRT)组合物(例如，口服MRT组合物)和用于制造MRT组合物的方法。用于制造MRT组合物的示例性方法可包括：采集粪便样本、将粪便样本提纯以形成纯化的样本、使纯化的样本稳定化以形成稳定的样本、将稳定的样本转变成固体、将一种或多种添加剂和/或辅料添加到固体中以形成治疗组合物、及将该治疗组合物封装。

USPTO Abstract

公开了微生物群恢复治疗(MRT)组合物(例如，口服MRT组合物)和用于制造MRT组合物的方法。用于制造MRT组合物的示例性方法可包括：采集粪便样本、将粪便样本提纯以形成纯化的样本、使纯化的样本稳定化以形成稳定的样本、将稳定的样本转变成固体、将一种或多种添加剂和/或辅料添加到固体中以形成治疗组合物、及将该治疗组合物封装。

Drugs covered by this patent

bendamustine-hydrochloride (BENDAMUSTINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN107921072A
Jurisdiction: CN
Classification: —
Expires: 2018-04-17
Drug substance claim: No
Drug product claim: No
Assignee: Rebiotix Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.